The same artificial intelligence that solved protein folding is now raising uncomfortable questions about who gets to use it, who profits from it, and whether science itself can remain open when the most powerful tools are locked behind corporate walls. At the upcoming 75th Lindau Nobel Laureate Meeting in July 2026, some of the world's most decorated scientists will confront a paradox: breakthrough AI models like AlphaFold have accelerated drug discovery beyond anyone's expectations, yet the companies controlling these tools are consolidating power in ways that could reshape the scientific process itself.

The tension is not new, but it is becoming urgent. When Google DeepMind released AlphaFold's protein structure database in 2021, the breakthrough was hailed as a gift to humanity. The team later won the Nobel Prize in Chemistry for the achievement. Yet today, as AI drug discovery startups race to commercialize protein-folding technology and major pharmaceutical companies like Pfizer and Eli Lilly sign exclusive partnerships worth hundreds of millions of dollars, the original promise of open science is colliding with the reality of proprietary control.

What Does It Mean When Big Tech Controls Scientific Tools?

The concern runs deeper than simple corporate gatekeeping. During a panel discussion scheduled for July 1, 2026, at the Lindau meeting, Nobel Laureates Geoffrey Hinton (2024 Physics), John M. Jumper (2024 Chemistry), Anne L'Huillier (2023 Physics), and William D. Phillips (1997 Physics) will explore how AI might fundamentally alter the scientific method itself. Jumper, who co-developed AlphaFold with Demis Hassabis at Google DeepMind, has publicly praised how responsibly scientists have used the tool. Yet Hinton, who resigned from Google in 2023, has become a prominent critic of unregulated AI progress, warning of existential risks and mass unemployment.

The stakes are particularly high for young researchers. If artificial intelligence can solve problems as quickly as a gifted postgraduate researcher but costs a fraction of their salary, what role remains for the next generation of scientists? This question will likely dominate discussions among this year's Young Scientists at the conference. Some experts, including Hassabis, have argued that AI could allow a single PhD student to produce the amount of work that would take an entire laboratory today. Others worry that PhD and postgraduate positions could simply disappear.

"People were messaging on LinkedIn at 2 a.m., saying, 'I am so excited I can't sleep,'" said Jack Dent, cofounder and president of Chai Discovery, describing the response when his company released a new antibody-design AI model.

Jack Dent, Cofounder and President, Chai Discovery

The commercialization of protein-folding AI is accelerating rapidly. Chai Discovery, a San Francisco-based startup founded in early 2024, has already signed partnerships with Eli Lilly and Pfizer after releasing its Chai-3 antibody design model. The company is now in talks to raise an additional $400 million at a valuation of $3.4 billion, according to exclusive reporting from Forbes. This follows a broader investment surge: venture capital poured $11.4 billion into AI drug discovery companies globally in 2025, more than double the $5.6 billion invested in 2024.

How Are Companies Reshaping the AI Drug Discovery Landscape?

The business model emerging around protein-folding AI differs markedly from traditional drug development. Most AI drug discovery companies develop their own pipelines of therapeutics, betting that blockbuster drugs will generate enormous returns. Chai Discovery took a different approach, selling access to its technology platform instead. This strategy has proven remarkably effective at attracting pharmaceutical partners.

• Chai's Competitive Advantage: The startup offers its earliest Chai-1 protein-folding model for free, allowing potential pharmaceutical customers to test the technology before committing to paid partnerships with more advanced versions like Chai-3.
• Partnership Scale: Chai is in talks with more than 15 additional pharmaceutical companies beyond Pfizer and Eli Lilly, positioning itself to capture significant market share in AI-assisted drug discovery.
• Investor Confidence: Major venture capital firms including OpenAI, General Catalyst, Menlo Ventures, and Oak HC/FT have invested more than $225 million in Chai, signaling strong belief in the company's business model and technology.

The timeline for real-world impact remains uncertain. Eli Lilly's chief information and digital officer told Forbes in March that given regulatory approval timelines, it would likely be the "mid-2030s, if not late-2030s" before any AI-developed medicines reach the market. Despite this long horizon, the pharmaceutical industry is treating AI protein-folding as a transformative technology worth betting billions on.

"The models were smoke and mirrors for a long time. We knew we had to make things literally 100 times better for it to be valuable for real drug discovery programs," said Josh Meier, cofounder and CEO of Chai Discovery.

Josh Meier, Cofounder and CEO, Chai Discovery

Chai's founders, Josh Meier (30) and Jack Dent (29), represent a new generation of AI entrepreneurs who grew up watching protein-folding breakthroughs unfold in real time. Meier worked at OpenAI, Meta's generative biology group, and AI drug discovery firm Absci before launching Chai. Dent spent time at Stripe, where he earned a reputation as one of the company's top engineers. By 2024, they sensed that "everything in AI was about to start working big time, and the protein discovery field was lagging by a few years," Dent explained.

How to Evaluate AI Drug Discovery Partnerships

• Technology Access Model: Assess whether companies offer tiered access to their AI tools, from free basic models to premium versions, which can indicate commitment to broader scientific adoption versus pure profit maximization.
• Partnership Scope: Consider the number and diversity of pharmaceutical partners a startup has secured, as this suggests both the credibility of the technology and the company's ability to scale impact across the industry.
• Timeline Expectations: Understand that AI-discovered drugs typically require 10 to 15 years for regulatory approval, so near-term revenue comes from licensing fees and partnerships rather than drug sales.

Who Controls Access to Scientific Breakthroughs?

The concentration of AI protein-folding technology in the hands of a few corporations raises fundamental questions about scientific accessibility and equity. Companies developing these technologies argue that they democratize science by offering open-access, cloud-based AI tools and quantum computing services. However, the hardware delivering these tools is concentrated in a clutch of powerful corporations, who also retain the most advanced versions of the technologies for themselves and aggressively recruit top talent from around the world.

Whether this arrangement is healthy and sustainable for science and society remains an open question. The Lindau Nobel Laureate Meeting will bring together some of the world's leading minds to grapple with these issues. The conversation will extend beyond current applications of AI in drug discovery to examine how these technologies might fundamentally reshape the scientific process itself, including questions about who gets to ask questions, who can access the tools to answer them, and who benefits from the discoveries that result.

For now, the momentum is clearly behind AI-driven drug discovery. Investors see enormous potential, pharmaceutical companies are signing major partnerships, and startups are racing to build better models. Yet the scientific community is increasingly aware that the choices made today about access, control, and governance will shape the future of research for decades to come.